Background/Aim: This study aimed to evaluate the effect of intensity-modulated radiation therapy (IMRT) on the clinical outcomes of patients with lymph node (LN) oligo-recurrence and a controlled primary tumor. Patients and Methods: We retrospectively reviewed the medical records of 21 patients diagnosed with LN oligo-recurrence who received IMRT with curative intent. Patients with tumor of various primary sites and histopathological types were included in this study. Results: The 3-year overall survival (OS) and in-field progression-free survival (PFS) rates were 75% and 52%, respectively. Statistical analysis showed that lower dose to the gross tumor volume (GTV) and larger GTV were significantly associated with poorer OS; adenocarcinoma and lower dose to GTV were significantly associated with poorer in-field PFS. No patients experienced severe adverse events. Conclusion: IMRT may provide a safe and effective treatment for patients with LN oligo-recurrence. Tumor dose-escalation sparing normal tissue using IMRT technology may improve the OS and in-field PFS.

中文翻译：

---

淋巴结寡复发的调强放射治疗

背景/目的：本研究旨在评估调强放射治疗 (IMRT) 对淋巴结 (LN) 寡复发和受控原发肿瘤患者临床结果的影响。患者和方法：我们回顾性审查了 21 名被诊断为 LN 寡复发并接受 IMRT 治疗的患者的医疗记录。本研究包括具有各种原发部位和组织病理学类型的肿瘤的患者。结果：3 年总生存率 (OS) 和场内无进展生存率 (PFS) 分别为 75% 和 52%。统计分析表明，较低的总肿瘤体积（GTV）剂量和较大的 GTV 与较差的 OS 显着相关；腺癌和较低的 GTV 剂量与较差的现场 PFS 显着相关。没有患者出现严重的不良事件。结论： IMRT 可为 LN 寡复发患者提供安全有效的治疗。使用 IMRT 技术增加肿瘤剂量保留正常组织可能会改善 OS 和场内 PFS。